|
|
|
|
The stability of a drug directly affects the dose a patient receives. The dose received depends on the way the compound is metabolised or accumulated in the body. This metabolism is a key determinant of drug bioavailability. A drug that is rapidly metabolised may require multiple daily dosing or continuous infusion to maintain a concentration in the bloodstream or target organ that is sufficient to elicit a therapeutic effect. However, a slowly metabolised drug may remain in the body for long periods, potentially causing toxic build-up.
Hepatocytes contain enzymes for both phase I (oxidation, reduction and/or hydrolysis of test compound) and phase II (conjugation of test compounds or metabolites) metabolism. |
 |
LGC Standards offers new IRMM reference material for C-reactive protein
Updated reference material for C-reactive protein available from LGC Standards
Διαβάστε περισσότερα >>
GM crops: protesters go back to the battlefields
A decade ago anti-GM protesters tore up fields and Britain roundly rejected so-called 'Frankenfood'. Now, as researchers trial new crops, activists...
Διαβάστε περισσότερα >>
